Ajay K Nooka MD

PubMed

• AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies.
  Amritpal Singh, Ajay K Nooka, Gourav Modanwal, Nieraj Jain, Madhav V Dhodapkar
  European Journal of Cancer. 2025-10-16
• Current experiences with teclistamab in patients with multiple myeloma and renal impairment.
  Meletios A Dimopoulos, Yael C Cohen, Aurore Perrot, Matthew J Pianko, Edward A Faber
  Expert Review of Hematology. 2025-10-02
• Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.
  Alyssa M Duffy, Anshika Goenka, Maryam I Azeem, Azmain Taz, Sayalee V Potdar
  The Journal of Clinical Investigation. 2025-10-01

Abstracts/Posters

• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Ajay K Nooka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all